Pretreatment plasma TGF beta 1 levels are prognostic for survival but not morbidity following radiation therapy of carcinoma of the cervix.

2.50
Hdl Handle:
http://hdl.handle.net/10541/86690
Title:
Pretreatment plasma TGF beta 1 levels are prognostic for survival but not morbidity following radiation therapy of carcinoma of the cervix.
Authors:
Dickson, Jeanette; Davidson, Susan E; Hunter, Robin D; West, Catharine M L
Abstract:
PURPOSE: To determine whether pretreatment plasma-transforming growth factor beta 1 (TGF beta 1) levels are prognostic for tumor control and late morbidity following radiation therapy in carcinoma of the cervix. METHODS AND MATERIALS: The study was comprised of 79 patients undergoing radiotherapy with curative intent for Stage I-III carcinoma of the cervix. TGF beta 1 levels were analyzed using ELISA. Late morbidity was measured using the Franco-Italian glossary. Data were available for the pretreatment levels of circulating tumor markers that represent disease burden, and for peripheral blood lymphocyte radiosensitivity measured as SF2. RESULTS: Pretreatment TGF beta 1 levels were a significant prognostic factor for survival and local control. There were weak significant correlations of TGF beta 1 levels with disease stage and the levels of circulating tumor markers (CA125, TPA). There was a weak significant correlation between TGF beta 1 levels and normal cell radiosensitivity (lymphocyte SF2). There was no relationship between TGF beta 1 levels and grade of morbidity and pretreatment TGF beta 1 levels were not a significant prognostic factor for the probability of developing late morbidity. CONCLUSION: In carcinoma of the cervix, pretreatment TGF beta 1 levels reflect tumor burden and are a significant prognostic factor for survival. Despite an underlying weak relationship of TGF beta 1 levels with intrinsic normal cell radiosensitivity, pretreatment levels are not prognostic for the probability of developing late complications. This finding does not rule out the possible usefulness of measurements toward the end of treatment once tumor burden has been reduced.
Affiliation:
CRC Experimental Radiation Oncology Group, Paterson Institute for Cancer Research, Manchester, United Kingdom.
Citation:
Pretreatment plasma TGF beta 1 levels are prognostic for survival but not morbidity following radiation therapy of carcinoma of the cervix. 2000, 48 (4):991-5 Int. J. Radiat. Oncol. Biol. Phys.
Journal:
International Journal of Radiation Oncology, Biology, Physics
Issue Date:
1-Nov-2000
URI:
http://hdl.handle.net/10541/86690
DOI:
10.1016/S0360-3016(00)00729-X
PubMed ID:
11072155
Type:
Article
Language:
en
ISSN:
0360-3016
Appears in Collections:
All Christie Publications ; All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorDickson, Jeanetteen
dc.contributor.authorDavidson, Susan Een
dc.contributor.authorHunter, Robin Den
dc.contributor.authorWest, Catharine M Len
dc.date.accessioned2009-11-23T12:09:28Z-
dc.date.available2009-11-23T12:09:28Z-
dc.date.issued2000-11-01-
dc.identifier.citationPretreatment plasma TGF beta 1 levels are prognostic for survival but not morbidity following radiation therapy of carcinoma of the cervix. 2000, 48 (4):991-5 Int. J. Radiat. Oncol. Biol. Phys.en
dc.identifier.issn0360-3016-
dc.identifier.pmid11072155-
dc.identifier.doi10.1016/S0360-3016(00)00729-X-
dc.identifier.urihttp://hdl.handle.net/10541/86690-
dc.description.abstractPURPOSE: To determine whether pretreatment plasma-transforming growth factor beta 1 (TGF beta 1) levels are prognostic for tumor control and late morbidity following radiation therapy in carcinoma of the cervix. METHODS AND MATERIALS: The study was comprised of 79 patients undergoing radiotherapy with curative intent for Stage I-III carcinoma of the cervix. TGF beta 1 levels were analyzed using ELISA. Late morbidity was measured using the Franco-Italian glossary. Data were available for the pretreatment levels of circulating tumor markers that represent disease burden, and for peripheral blood lymphocyte radiosensitivity measured as SF2. RESULTS: Pretreatment TGF beta 1 levels were a significant prognostic factor for survival and local control. There were weak significant correlations of TGF beta 1 levels with disease stage and the levels of circulating tumor markers (CA125, TPA). There was a weak significant correlation between TGF beta 1 levels and normal cell radiosensitivity (lymphocyte SF2). There was no relationship between TGF beta 1 levels and grade of morbidity and pretreatment TGF beta 1 levels were not a significant prognostic factor for the probability of developing late morbidity. CONCLUSION: In carcinoma of the cervix, pretreatment TGF beta 1 levels reflect tumor burden and are a significant prognostic factor for survival. Despite an underlying weak relationship of TGF beta 1 levels with intrinsic normal cell radiosensitivity, pretreatment levels are not prognostic for the probability of developing late complications. This finding does not rule out the possible usefulness of measurements toward the end of treatment once tumor burden has been reduced.en
dc.language.isoenen
dc.subjectCancer Stagingen
dc.subjectBiological Tumour Markersen
dc.subjectUterine Cervical Canceren
dc.subject.meshAdenocarcinoma-
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAged, 80 and over-
dc.subject.meshAnalysis of Variance-
dc.subject.meshCA-125 Antigen-
dc.subject.meshCarcinoma, Squamous Cell-
dc.subject.meshFalse Negative Reactions-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshLymphocytes-
dc.subject.meshMiddle Aged-
dc.subject.meshNeoplasm Staging-
dc.subject.meshPrognosis-
dc.subject.meshSensitivity and Specificity-
dc.subject.meshTissue Polypeptide Antigen-
dc.subject.meshTransforming Growth Factor beta-
dc.subject.meshTransforming Growth Factor beta1-
dc.subject.meshTumor Markers, Biological-
dc.subject.meshUterine Cervical Neoplasms-
dc.titlePretreatment plasma TGF beta 1 levels are prognostic for survival but not morbidity following radiation therapy of carcinoma of the cervix.en
dc.typeArticleen
dc.contributor.departmentCRC Experimental Radiation Oncology Group, Paterson Institute for Cancer Research, Manchester, United Kingdom.en
dc.identifier.journalInternational Journal of Radiation Oncology, Biology, Physicsen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.